Journal of Clinical Endocrinology & Metabolism, Vol 81, 860-863, Copyright © 1996 by Endocrine Society

ARTICLES

Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM)

JM Gibson, M Westwood, RJ Young and A White
Department of Medicine, Manchester University, UK.

IGF-I and -II levels are altered in patients with atherogenic lipid profiles and may contribute to the development of macrovascular disease in NIDDM. We examined cardiovascular risk factors, IGF-I, IGF-II and IGFBP-1 in 74 NIDDM patients analysed as a whole group and according to treatment type. IGF-I was not significantly associated with cardiovascular risk factors but IGF-II levels correlated positively with total and LDL cholesterol most markedly in the diet treated group (0.72, p < 0.01 and 0.76, p < 0.01 respectively). In the whole group reduced IGFBP-1 levels were significantly associated with factors known to increase cardiovascular risk: i.e. low HDL cholesterol (0.31, p < 0.01) and elevated blood pressure (-0.35, p < 0.01), BMI (-0.37, p < 0.01), insulin (-0.29, p < 0.01) and proinsulin (-0.24, p < 0.01). In the treatment groups IGFBP-1 was lower in patients on diet alone (n = 11, 42.6 +/- 11.6 mu g/l) and sulphonylurea +/- insulin (n = 39, 53.2 +/- 7.6 mu g/l) relative to insulin treatment (n = 24, 103.0 +/- 19, 7 mu g/l, p < 0.05). The lower levels of IGFBP-1 were not due to a significant change in phosphorylation status from the highly phosphorylated circulating form since lesser and non-phosphorylated variants were undetectable in 53/74 patients. Multiple regression analysis revealed the best predictors of IGFBP-1 were BMI and MAP (R2 = 0.2. p < 0.001) and for blood pressure, IGFBP-1 and age (R2 = 0.47, p < 0.001). These findings indicate that in NIDDM patients low IGFBP-1 levels are associated with multiple factors predisposing to atherogenesis.

This article has been cited by other articles:

				S. Saydah, B. Graubard, R. Ballard-Barbash, and D. Berrigan Insulin-like Growth Factors and Subsequent Risk of Mortality in the United States Am. J. Epidemiol., September 1, 2007; 166(5): 518 - 526. [Abstract] [Full Text] [PDF]

				R. H. Stephens, P. McElduff, A. H. Heald, J. P. New, J. Worthington, W. E. Ollier, and J. M. Gibson Polymorphisms in IGF-Binding Protein 1 Are Associated With Impaired Renal Function in Type 2 Diabetes Diabetes, December 1, 2005; 54(12): 3547 - 3553. [Abstract] [Full Text] [PDF]

				C. F. Liew, S. D. Wise, K. P. Yeo, and K. O. Lee Insulin-Like Growth Factor Binding Protein-1 Is Independently Affected by Ethnicity, Insulin Sensitivity, and Leptin in Healthy, Glucose-Tolerant Young Men J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1483 - 1488. [Abstract] [Full Text] [PDF]

				K. Kaushal, A. H. Heald, K. W. Siddals, M. S. Sandhu, D. B. Dunger, J. M. Gibson, and N. J. Wareham The Impact of Abnormalities in IGF and Inflammatory Systems on the Metabolic Syndrome Diabetes Care, November 1, 2004; 27(11): 2682 - 2688. [Abstract] [Full Text] [PDF]

				U. Riserus, J. Arnlov, K. Brismar, B. Zethelius, L. Berglund, and B. Vessby Sagittal Abdominal Diameter Is a Strong Anthropometric Marker of Insulin Resistance and Hyperproinsulinemia in Obese Men Diabetes Care, August 1, 2004; 27(8): 2041 - 2046. [Abstract] [Full Text] [PDF]

				K. Wolk, S. C. Larsson, B. Vessby, A. Wolk, and K. Brismar Metabolic, Anthropometric, and Nutritional Factors as Predictors of Circulating Insulin-Like Growth Factor Binding Protein-1 Levels in Middle-Aged and Elderly Men J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1879 - 1884. [Abstract] [Full Text] [PDF]

				G. A. Laughlin, E. Barrett-Connor, M. H. Criqui, and D. Kritz-Silverstein The Prospective Association of Serum Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-1 Levels with All Cause and Cardiovascular Disease Mortality in Older Adults: The Rancho Bernardo Study J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 114 - 120. [Abstract] [Full Text] [PDF]

				C. Livingstone and G. A. Ferns Review: Insulin-like growth factor-related proteins and diabetic complications The British Journal of Diabetes & Vascular Disease, September 1, 2003; 3(5): 326 - 331. [Abstract] [PDF]

				S. B. Wheatcroft, M. T. Kearney, A. M. Shah, D. J. Grieve, I. L. Williams, J. P. Miell, and P. A. Crossey Vascular Endothelial Function and Blood Pressure Homeostasis in Mice Overexpressing IGF Binding Protein-1 Diabetes, August 1, 2003; 52(8): 2075 - 2082. [Abstract] [Full Text] [PDF]

				A. W. van den Beld, M. L. Bots, J. A. M. L. L. Janssen, H. A. P. Pols, S. W. J. Lamberts, and D. E. Grobbee Endogenous Hormones and Carotid Atherosclerosis in Elderly Men Am. J. Epidemiol., January 1, 2003; 157(1): 25 - 31. [Abstract] [Full Text] [PDF]

				E. S. Leinonen, J. T. Salonen, R. M. Salonen, R. A. Koistinen, P. J. Leinonen, S. S. Sarna, and M.-R. Taskinen Reduced IGFBP-1 Is Associated With Thickening of the Carotid Wall in Type 2 Diabetes Diabetes Care, October 1, 2002; 25(10): 1807 - 1812. [Abstract] [Full Text] [PDF]

				A. H. Heald, K.W. Siddals, W. Fraser, W. Taylor, K. Kaushal, J. Morris, R. J. Young, A. White, and J. M. Gibson Low Circulating Levels of Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) Are Closely Associated With the Presence of Macrovascular Disease and Hypertension in Type 2 Diabetes Diabetes, August 1, 2002; 51(8): 2629 - 2636. [Abstract] [Full Text] [PDF]

				S. Zaina, L. Pettersson, B. Ahren, L. Branen, A. B. Hassan, M. Lindholm, R. Mattsson, J. Thyberg, and J. Nilsson Insulin-like Growth Factor II Plays a Central Role in Atherosclerosis in a Mouse Model J. Biol. Chem., February 1, 2002; 277(6): 4505 - 4511. [Abstract] [Full Text] [PDF]

				C. D Byrne Programming other hormones that affect insulin: Type 2 diabetes Br. Med. Bull., November 1, 2001; 60(1): 153 - 171. [Abstract] [Full Text] [PDF]

				M. Paassilta, K. Kervinen, M. Linnaluoto, and Y. A. Kesaniemi Alcohol Withdrawal–Induced Change in Lipoprotein(a) : Association With the Growth Hormone/Insulin-like Growth Factor-I (IGF-I)/IGF-Binding Protein-1 (IGFBP-1) Axis Arterioscler. Thromb. Vasc. Biol., April 1, 1998; 18(4): 650 - 654. [Abstract] [Full Text] [PDF]

				E. R. Christ, P. V. Carroll, E. Albany, A. M. Umpleby, P. J. Lumb, A. S. Wierzbicki, P. H. Sonksen, and D. L. Russell-Jones Effect of IGF-I therapy on VLDL apolipoprotein B100 metabolism in type 1 diabetes mellitus Am J Physiol Endocrinol Metab, May 1, 2002; 282(5): E1154 - E1162. [Abstract] [Full Text] [PDF]